The Macrolide-Clarithromycin Project:
By middle of March 2020, we presented to the Argentine National Health
Ministry our novel idea to treat COVID-19 infected patients with only a
Macrolide, Clarithromycin, as a single agent. Also we proposed to use it
for the prophylaxis of medical personnel largely exposed and at high
risk. Even as a strategy to eradicate the virus from earth. In a way to
rapidly make public this information and central idea: the use of
clarithromycin as single agent for treatment and prophylaxis of COVID-19
we made a video and a special page for internet as well as a short
preliminary communication on a special-scientific site of the web
(22)(23)(24). Until that date, in which we presented this project to our
regulatory authorities, and according to the available scientific
literature and published information, no other research medical group in
the world had previously done or proposed a controlled clinical trial to
test the pure antiviral efficacy of any macrolide for COVID-19, as a
single agent, without the association of any other drug with it. Up to
date we have not received any answer yet from our Ministry of Health in
this direction and in this short period of time several other groups
from different parts of the world started thinking in similar but not
identical ideas.